Corporate Presentation September 2025 1 2 Building a Leading Allergy and Immunology Company Transforming science that WORKS… …into therapies that patients WANT. HEREDITARY ANGIOEDEMA (HAE) FLS This presentation contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: the expected timing of receipt of topline results from the navenibart ALPHA-ORBIT Phase 3 trial; the goals and objectives of the ALPHA-ORBIT Phase ...